Status:

WITHDRAWN

Choroidal Blood Flow Response to Hand-grip Test in Progressive Glaucoma

Lead Sponsor:

University Hospital, Basel, Switzerland

Conditions:

Primary Open Angle Glaucoma

Eligibility:

All Genders

30-80 years

Brief Summary

The present study is designed to compare the response of choroidal blood flow to the hand-grip test in glaucoma patients with and without visual field progression.

Detailed Description

Glaucoma is a worldwide leading cause of blindness. The key features of glaucoma are damage to the optic nerve head and progressive visual field defect, which is not necessarily only related to an inc...

Eligibility Criteria

Inclusion

  • Patients fulfilling two out of three of the following criteria in one or both eyes: a) typical glaucomatous disc, b) visual field damage (a cluster of three points (except rim points) in at least one hemifield reduced by 5 dB or greater and including at least one point reduced by 10 dB or greater; a cluster of two points reduced by 10 dB or greater; or three adjacent points on the nasal horizontal meridian that differed by 5 dB or greater from their mirror points on the opposite side of the meridian), c) intraocular pressure above 21 mm Hg at least at one occasion. Furthermore, patients need to have a series of at least 5 visual field examinations, after exclusion of the first test, for assessment of progression.
  • \-

Exclusion

  • Ametropia \> 3dpt
  • Inadequate transparency of ocular media as defined by physical examination
  • Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
  • Any abnormality which in the physician's view would prevent reliable applanation tonometry or LDF of at least one eye
  • History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis
  • History of ocular trauma or intraocular surgery within the past 6 months
  • History of infection or inflammation within the past 3 months
  • History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment
  • Patients with a significant history and/or active alcohol or drug abuse (significant is defined as that which in the opinion of the investigator may either put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study).

Key Trial Info

Start Date :

March 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00284440

Start Date

March 1 2006

End Date

June 1 2011

Last Update

March 10 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Eye Clinic

Basel, Canton of Basel-City, Switzerland, 4031